Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors

Cancer Gene Therapy

Volumn 5, Issue 4, 1998, Pages 236-246

  Philip, Ramila ^a,b   Brunette, Elisa ^a   Ashton, Jean ^a   Alters, Susan ^a   Gadea, Jose ^a   Sorich, Martin ^a   Yau, Josephine ^a   O'Donoghue, Gerard ^a   Lebkowski, Jane ^a   Okarma, Thomas ^a   Philip, Mohan ^a  

^a RPR Gencell   (United States)

^b NONE   (United States)

Author keywords

Cytotoxic T lymphocyte; Dendritic cell; Liposome; Transfection; Tumor associated antigen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LIPOSOME; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; GENE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; MONOCYTE; PHYSIOLOGY; TRANSGENE;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DENDRITIC CELLS; DEPENDOVIRUS; GENES, MHC CLASS I; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; LIPOSOMES; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTES; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSGENES;

EID: 0032113879     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
2. Flamand V, Sornasse K, Tielemans O, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994;24:605-610.
3. Paglia P, Chiodoni C, Rodolfo M. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
4. Porgador A, Shyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol. 1996;156:2918-2926.
5. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182: 255-260.
6. Ossevoort MA, Feltkamp MCW, Van Veen KJH, et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human Papillomavirus type 16-induced tumor. J Immunother. 1995;18:86-94.
7. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med. 1995;1:1297-1302.
8. Celluzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
9. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
10. + cytotoxic T lymphocytes by dendritic cells. J Exp Med. 1987;166:182-194.
11. Romani N, Koide S, Crowley M, et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med. 1989;169:1169-1178.
12. + helper T cells. J Exp Med. 1990;171:1315-1332.
13. Thomas R, Davis LS, Lipsky PE. Isolation and characterization of human peripheral blood dendritic cells. J Immunol 1993:150:821-834.
14. Grabbe S, Beissert S, Schwarz T, et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today. 1995;16:117-121.
15. Townsend AR, McMichael AJ, Carter NP, et al. Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell. 1984;39:13-25.
16. Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell. 1985;42:457-467.
17. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994;24:605-610.
18. 4Ig gene family by diffuse large-cell lymphoma. Blood. 1995;86:3072-3082.
19. Kawakami Y, Eliyahu S, Delgado C, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3515-3519.
20. Coulic PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma. J Exp Med. 1994;180:35-42.
21. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489-495.
22. Philip R, Brunette E, Kilinski L, et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol. 1994;14:2411-2418.
23. Philip R, Clary B, Brunette E, et al. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res. 1996;2:59-68.
24. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
25. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
26. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 1995;55:1099-1104.
27. + bone marrow precursors cultured with c-kit ligand, granulocyte macrophage colony-stimulating factor, and TNF-α. J Immunol. 1995;154:5851-5861.
28. Huang MTF, Groman, CM. Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmid RNA. Nucleic Acids Res. 1990;18:937-947.
29. Pannetier C, Cochet M, Darche S, et al. The sizes of the CDR3: hypervariable regions of the murine T cell receptor B chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA. 1993;90:4319-4323.
30. Sensi M, Castelli C, Anichini A, et al. Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumor activity do not share the same TCR Vα and Vβ gene families. Melanoma Res. 1991;194:261-271.
31. Puisieux I, Even J, Pannetier C, et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol. 1994;153:2807-2817.
32. Alijagic S, Moller P, Artuc M, et al. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol. 1995;25:3100-3107.
33. Henderson R, Nimgaonkar M, Watkins S, et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 1996;56:3763-3770.
34. Reeves M, Royal R, Lam J, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56:5672-5677.
35. + T cells. J Clin Invest. 1994;94:797.
36. Spahn G, Ziegner M, Dorken B, et al. Liposomal MUC-1-cDNA transfer into dendritic cells for the use as tumor vaccine. 4th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, Supplement #104. Milan, Italy: Ricerca Scientìfica Ed Educazione Permanente, University of Milan; 1996:356.
37. Arthur J, Butterfield L, Roth M, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
38. Talib S, Okarma T, Lebkowski J. Differential expression of human nicotinic acetylcholine receptor α subunit variants in muscle and non-muscle tissues. Nucleic Acids Res. 1993;21:233-237.
39. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 1987;6:2337-2342.
40. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. J Biol Chem. 1991;266:5256-5259.
41. Bakker A, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 1995;55:5330-5334.
42. Marincola FM, Rivoltini L, Salgaller ML, et al. Differential anti-MART1/Melan A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphas Tumor Immunol. 1996;19:266-277.
43. Nanda NK, and Sercarz EE. Induction of anti-self immunity to cure cancer. Cell. 1995;82:13.
44. Sensi M, Castelli C, Salvi S, et al. Expansion of major histocompatability complex-restricted antimelanoma cytotoxic T cell lymphocyte clones with identical T cell receptors from tumor infiltrating lymphocytes. J Immunother. 1992;12:207-211.
45. Shilyansky J, Nishimura MI, Yannelli JR, et al. T-cell receptor usage by melanoma-specific clonal and high oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci USA. 1994;91:2829-2833.
46. Cole DJ, Weil DP, Shamamian P, et al. Identification of MART-1-specific T cell receptors: T cells utilizing distinct T cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 1994;54:5265-5268.